We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.84%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$372M
AUM Growth
+$4.91M
Cap. Flow
-$21.9M
Cap. Flow %
-5.89%
Top 10 Hldgs %
47.82%
Holding
97
New
8
Increased
10
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$3.96M
2
MDWD icon
MediWound
MDWD
+$2.57M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.16M
4
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.4M
5
KURA icon
Kura Oncology
KURA
+$1.37M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.71M
2
NTUS
Natus Medical Inc
NTUS
+$4.71M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.96M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.65M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERO
76
DELISTED
Venus Concept
VERO
$426K 0.11%
5,868
– –
MASI
77
DELISTED
Masimo
MASI
$423K 0.11%
3,000
– –
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
$377K 0.1%
351,064
– –
INGN icon
79
Inogen
INGN
$164M
$364K 0.1%
15,000
– –
MGNX icon
80
MacroGenics
MGNX
$257M
$346K 0.09%
100,000
-92,000
-48% -$352K
BMEA icon
81
Biomea Fusion
BMEA
$91.3M
$339K 0.09%
34,625
-102,310
-75% -$1.17M
SPRO icon
82
Spero Therapeutics
SPRO
$73M
$250K 0.07%
+125,000
New +$124K
LCTX icon
83
Lineage Cell Therapeutics
LCTX
$274M
$158K 0.04%
140,000
– –
REUN
84
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$138K 0.04%
96,585
-284,243
-75% -$1.01M
CGEN icon
85
Compugen
CGEN
$228M
$135K 0.04%
205,202
– –
PHAS
86
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$57K 0.02%
321,856
-56,755
-15% -$57.9K
ANNX icon
87
Annexon
ANNX
$886M
– –
-40,796
Closed -$154K
CNTB
88
Connect Biopharma Holdings
CNTB
$139M
– –
-250,000
Closed -$218K
LVTX
89
DELISTED
LAVA Therapeutics
LVTX
– –
-128,335
Closed -$379K
MDGL icon
90
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-3,100
Closed -$222K
RIGL icon
91
Rigel Pharmaceuticals
RIGL
$750M
– –
-39,007
Closed -$441K
WVE icon
92
Wave Life Sciences
WVE
$1.2B
– –
-372,361
Closed -$1.21M
ASLN
93
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-8,593
Closed -$170K
TPTX
94
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-48,452
Closed -$3.65M
RDUS
95
DELISTED
Radius Health, Inc.
RDUS
– –
-91,935
Closed -$953K
NTUS
96
DELISTED
Natus Medical Inc
NTUS
– –
-143,600
Closed -$4.71M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, DAFNA Capital Management held 97 positions worth $372M, up 1.3% from $367M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $21.9M in Q3 2022, closing 10 positions and reducing 34 holdings. Its most notable exit was Natus Medical Inc, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in MediWound worth $1.99M.

  • DAFNA Capital Management's largest Q3 2022 buy was MediWound: 204,082 shares worth $1.99M.
  • DAFNA Capital Management added most to Revolution Medicines in Q3 2022, an estimated $3.96M increase.
  • DAFNA Capital Management's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $6.71M.
  • DAFNA Capital Management fully exited Natus Medical Inc in Q3 2022, selling an estimated $4.71M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $372M portfolio in Q3 2022.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q3 2022.
  • DAFNA Capital Management's portfolio value rose 1.3% quarter-over-quarter to $372M.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.